Literature DB >> 6987872

The role of hypertension in hemodialysis-associated atherosclerosis.

F Vincenti, W J Amend, J Abele, N J Feduska, O Salvatierra.   

Abstract

Atherosclerosis in 50 nondiabetic patients undergoing hemodialysis was assessed at the time of renal transplantation by intraoperative examination and histologic evaluation of the iliac vasculature. Patients were grouped accordingly: minimal (group 1), moderate (group 2) or severe (group 3) atherosclerosis. Sixty-two per cent of the patients had atherosclerosis, half of them with severe involvement. No sex differences were noted. There was a significant correlation between the patient's age and the degree of atherosclerosis (p less than 0.02). Thirty-five per cent of the patients under 30 years of age had atherosclerosis whereas similarly studied nonuremic control subjects had no atherosclerosis. Metabolic and lipid abnormalities, and duration of hemodialysis did not correlate with degree of atherosclerosis. Hypertension was present in 90 per cent of the patients in groups 2 and 3. When patients between the ages of 25 and 40 years were selected, atherosclerosis was present only in previously hypertensive patients (p less than 0.02). Atherosclerosis may not be accelerated by hemodialysis and may be prevented by more stringent control of hypertension in uremia.

Entities:  

Mesh:

Year:  1980        PMID: 6987872     DOI: 10.1016/0002-9343(80)90104-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Current understanding of optimal blood pressure goals in dialysis patients.

Authors:  Paul Light
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 2.  Osteoporosis and atherosclerosis in chronic renal failure.

Authors:  Y Nishizawa; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Plasma oxalate concentration and secondary oxalosis in patients with chronic renal failure.

Authors:  C R Tomson; S M Channon; I S Parkinson; A R Morley; T W Lennard; N R Parrott; M F Laker
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

4.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

Review 5.  [Reno-cardiac interactions in kidney failure (author's transl)].

Authors:  P Kramer; M Schmidt-Lauber; N Langenheim; W Zwehl; G Sold; H Luig; D Matthaei; H J Gröne; H V Henning; F Scheler
Journal:  Klin Wochenschr       Date:  1980-10-01

Review 6.  Role of the kidney in hormone metabolism and its implications in clinical medicine.

Authors:  D S Emmanouel; M D Lindheimer; A I Katz
Journal:  Klin Wochenschr       Date:  1980-10-01

7.  Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure.

Authors:  N M Al-Saady; E W Leatham; S Gupta; J T Kwan; J B Eastwood; C A Seymour
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

Review 8.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.